UBS Group
SUPN icon

UBS Group’s Supernus Pharmaceuticals SUPN Stock Holding History

UBS Group’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-45,800
Closed -$1.97M – 7978
2017
Q2 		$1.97M Hold
45,800
– – ﹤0.01% 3025
2017
Q1 		$1.43M Buy
+45,800
New +$1.23M ﹤0.01% 3233

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

UBS Group's SUPN Position: Q2 2026 in Review

UBS Group increased its Supernus Pharmaceuticals (SUPN) stake by 5.4% in Q2 2026, buying an estimated $544K and bringing the position to 220,457 shares worth $10.3M. The position accounts for ﹤0.01% of the portfolio, ranked #3416.

UBS Group first reported a position in SUPN in Q4 2014 and has held it in 47 quarters since. The position peaked at $25.8M in Q3 2025. 335 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • UBS Group held 220,457 shares of Supernus Pharmaceuticals worth $10.3M as of Q2 2026.
  • UBS Group bought 11,333 Supernus Pharmaceuticals shares in Q2 2026, an estimated $544K.
  • Supernus Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #3416 holding.
  • UBS Group first reported a position in Supernus Pharmaceuticals in Q4 2014 and has held it in 47 quarters since.
  • UBS Group's Supernus Pharmaceuticals position peaked at $25.8M in Q3 2025.
  • 335 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.